Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase

Vaccine

Volumn 21, Issue 23, 2003, Pages 3290-3300

  Tallima, Hatem ^a   Montash, Mona ^a   Vepřek, Pavel ^b   Velek, Jiři ^b   Ježek, Jan ^b   El Ridi, Rashika ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Glyceraldehyde 3 phosphate dehydrogenase; Schistosoma mansoni; Synthetic peptide vaccine

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; SCHISTOSOMA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FERTILITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SEQUENCE HOMOLOGY;

EID: 0038543267     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00180-4     Document Type: Article

References (42)

1. Dunne D, Mountford A. Resistance to infection in humans and animal models. In: Mahmoud AAF, editor. Schistosomiasis. London: Imperial College Press; 2001. p. 133-212.
2. McManus D.P. The search for a vaccine against schistosomiasis - a difficult path but an achievable goal. Immunol. Rev. 171:1999;149-161.
3. Dessein A.J., Begley M., Demeure C.et al. Human resistance to Schistosoma mansoni is associated with IgG reactivity to a 37-kDa larval surface antigen. J. Immunol. 140(8):1988;2727-2736.
4. El Ridi R., Farouk F., Sherif M.et al. T and B cell reactivity to a 42-kDa protein is associated with human resistance to both schistosomiasis mansoni and haematobium. J. Infect. Dis. 177(5):1998;1364-1372.
5. El Ridi R., Shoemaker C.B., Farouk F., El Sherif N.H., Afifi A. Human T- and B-cell responses to Schistosoma mansoni recombinant glyceraldehyde 3-phosphate dehydrogenase correlate with resistance to reinfection with S. mansoni or Schistosoma haematobium after chemotherapy. Infect. Immun. 69(1):2001;237-244.
6. Goudot-Crozel V., Caillol D., Djabali M., Dessein A.J. The major parasite surface antigen associated with human resistance to schistosomiasis is a 37-kDa glyceraldehyde-3P-dehydrogenase. J. Exp. Med. 170(6):1989;2065-2080.
7. Abath F.G.C. Development of vaccines against human parasitic diseases: tools, current status and perspectives. Exp. Opin. Invest. Drugs. 9(2):2000;301-310.
8. Wolowczuk I., Auriault C., Gras-Masse H.et al. Protective immunity in mice vaccinated with the Schistosoma mansoni P-28-1 antigen. J. Immunol. 142(4):1989;1342-1350.
9. Reynolds S.R., Shoemaker C.B., Harn D.A. T and B cell epitope mapping of Sm23, an integral membrane protein of Schistosoma mansoni. J. Immunol. 149(12):1992;3995-4001.
10. Reynolds S.R., Dahl C.E., Harn D.A. T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase. J. Immunol. 152(1):1994;193-200.
11. El Ridi R., Mahrous A., Afifi A., Montash M., Velek J., Ježek J. Human and murine humoral immune recognition of multiple peptides from Schistosoma mansoni glyceraldehyde 3-P dehydrogenase is associated with resistance to schistosomiasis. Scand. J. Immunol. 54(5):2001;477-485.
12. El Ridi R., Abdel Tawab N., Guirguis N. Schistosoma mansoni: identification and protective immunity of adult worm antigens recognized by T lymphocytes of outbred Swiss mice immunized with irradiated cercariae. Exp. Parasitol. 76(3):1993;265-277.
13. Osman A., El Ridi R., Guirguis N., Dean D.A. Identification of Schistosoma mansoni antigens recognized by T cells of C57BL/6 mice immunized with gamma-irradiated cercariae. J. Parasitol. 80(3):1994;421-431.
14. Antoni G., Mariani M., Presentini R.et al. Production and characterization of monoclonal antibodies to anti-human chorionic somatomammotropin by immunization with two free synthetic peptides. Mol. Immunol. 22(11):1985;1237-1241.
15. Atassi M.Z., Young C.R. Discovery and implications of the immunogenicity of free small synthetic peptides: powerful tools for manipulating the immune system and for production of antibodies and T cells of preselected submolecular specificities. Crit. Rev. Immunol. 5(4):1985;387-409.
16. Merrifield B. Solid-phase peptide synthesis. In: Gutte B, editor. Peptides, synthesis, structures, and applications. San Diego: Academic Press; 1995. p. 93-169.
17. Ježek J., Velková V., Kašièka V.et al. Side reaction during the deprotection of Cys (Acm) containing peptides with iodine. Synthesis of disulfide fragments from cathepsin D structure. Collect Czech Chem. Commun. 60:1995;1042-1049.
18. Smithers S.R., Terry R.J. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology. 55(4):1965;695-700.
19. Cheever A.W. Relative resistance of the eggs of human schistosomes to digestion in potassium hydroxide. Bull WHO. 43(4):1970;601-603.
20. Germain RN. Antigen processing and presentation. In: Paul WE, editor. Fundamental immunology. 4th ed. Philadelphia: Lippincott-Raven; 1999. p. 287-340.
21. Hosken N.A., Bevan M.J., Carbone F.R. Class I restricted presentation occurs without internalization or processing of exogenous antigenic peptides. J. Immunol. 142(4):1989;1079-1083.
22. Lanzavecchia A. Identifying strategies for immune intervention. Science. 260(5110):1993;937-943.
23. Bachmann M.F., Sebzda E., Kundig T.M.et al. T cell responses are governed by avidity and co-stimulatory thresholds. Eur. J. Immunol. 26(9):1996;2017-2022.
24. Harn D.A., Reynolds S.R., Chikunguwo S., Furlong S., Dahl C. Synthetic peptide vaccines for schistosomiasis. Pharm. Biotechnol. 6:1995;891-905.
25. Van Regenmortel MHV. Synthetic peptides as vaccines. In: van der Vliet PC, editor. Laboratory techniques in biochemistry and molecular biology, vol. 28. Amsterdam: Elsevier; 1999. p. 281-317.
26. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Nussenzweig R.S. The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Adv. Immunol. 60:1995;105-149.
27. Tam J.P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. U.S.A. 85(15):1988;5409-5413.
28. Tam J.P. Recent advances in multiple antigen peptide. J. Immunol. Methods. 196(1):1996;17-32.
29. El Ridi R, Lewis S, Afifi A, Shoemaker CB. Immunogenicity and protective capacity of Schistosoma mansoni recombinant glyceraldehyde 3-phosphate dehydrogenase, a candidate vaccine for human schistosomiasis. In: Proceedings of The SRP 1998 (Final) International Conference on Schistosomiasis, 15-19 March 1998, Cairo, Egypt.
30. Argiro L., Kohlstadt S., Henri S.et al. Identification of a candidate vaccine peptide on the 37 kDa Schistosoma mansoni GAPDH. Vaccine. 18(19):2000;2039-2048.
31. Argiro L., Henri S., Dessein H., Dessein A.J., Bourgois A. Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum. Vaccine. 17(1):1999;13-18.
32. Charrier-Ferrara S., Caillol D., Goudot-Crozel V. Complete sequence of the Schistosoma mansoni glyceraldehyde-3-phosphate dehydrogenase gene encoding a major surface antigen. Mol. Biochem. Parasitol. 56(2):1992;339-344.
33. Jankovic D., Wynn T.A., Kullberg M.C.et al. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFN-γ-dependent effector mechanisms. J. Immunol. 162(1):1999;345-351.
34. Capron A., Dessaint J.P. Effector and regulatory mechanisms in immunity to schistosomes: a heuristic view. Ann. Rev. Immunol. 3:1985;455-476.
35. Khalife J., Dunne D.W., Richardson B.A.et al. Functional role of human IgG subclasses in eosinophil-mediated killing of schistosomula of Schistosoma mansoni. J. Immunol. 142(12):1989;4422-4427.
36. Bickle Q.D., Ford M.J. Studies on the surface antigenicity and susceptibility to antibody-dependent killing of developing schistosomula using sera from chronically infected mice and mice vaccinated with irradiated cercariae. J. Immunol. 128(5):1982;2101-2106.
37. Moser G., Wassom D.L., Sher A. Studies of the antibody-dependent killing of schistosomula of Schistosoma mansoni employing haptenic target antigens. I. Evidence that the loss in susceptibility to immune damage undergone by developing schistosomula involves a change unrelated to the masking of parasite antigens by host molecules. J. Exp. Med. 152(1):1980;41-53.
38. Wilson RA. Cercariae to liver worms: development and migration in the mammalian host. In: Rollinson D, Simpson AJG, editors. The biology of schistosomes - from genes to latrines. London: Academic Press; 1987. p. 115-46.
39. Wilson R.A., Coulson P.S. Why don't we have a schistosomiasis vaccine? Parasitol. Today. 14(3):1998;97-99.
40. Sturrock RF. The schistosomes and their intermediate hosts. In: Mahmoud AAF, editor. Schistosomiasis. London: Imperial College Press; 2001. p. 7-83.
41. Skelly P.J., Shoemaker C.B. Rapid appearance and asymmetric distribution of glucose transporter SGTP4 at the apical surface of intramammalian-stage Schistosoma mansoni. Proc. Natl. Acad. Sci. U.S.A. 93(8):1996;3642-3646.
42. Skelly P.J., Pfeiffer R., Verrey F., Shoemaker C.B. SPRM11c, a heterodimeric amino acid permease light chain of the human parasitic platyhelminth, Schistosoma mansoni. Parasitology. 119(6):1999;569-576.